AbbVie Inc. ABBV financials

Healthcare & Pharma ยท Statements and segments from its SEC filings, 2011 to 2025.

AbbVie Inc. revenue, gross and operating margin, net income, free cash flow, cash and debt by quarter and by fiscal year, and revenue by segment, read from the company's own filings with the US Securities and Exchange Commission. Free to everyone; the Risk & Quality report that scores the company is the paid step.

  • revenue by region: United States, All other countries, Germany, Japan, Canada, China, France, United Kingdom, Spain, Italy, Brazil, Australia, The Netherlands

The numbers

Annual figures

LineFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$25.6B$28.2B$32.8B$33.3B$45.8B$56.2B$58.1B$54.3B$56.3B$61.2B
Gross profit$19.8B*$21.2B*$25B*$25.8B*$30.4B*$38.8B*$40.6B*$33.9B*$39.4B*$43B*
Operating income$9.3B$9.5B$6.4B$13B$11.4B$17.9B$18.1B$12.8B$9.1B$15.1B
Net income$6B$5.3B$5.7B$7.9B$4.6B$11.5B$11.8B$4.9B$4.3B$4.2B
EPS (diluted)$3.63$3.30$3.66$5.28$2.72$6.45$6.63$2.72$2.39$2.36
Operating cash flow$7B$10B$13.4B$13.3B$17.6B$22.8B$24.9B$22.8B$18.8B$19B
Free cash flow$6.6B*$9.4B*$12.8B*$12.8B*$16.8B*$22B*$24.2B*$22.1B*$17.8B*$17.8B*
Cash & equivalents$5.1B$9.3B$7.3B$39.9B$8.4B$9.7B$9.2B$12.8B$5.5B$5.2B
Total debt$36.4B$31B$35B$67.2B$84.9B$76B$63.1B$59.2B$66.8B$64.5B
Gross margin77.3%75.0%76.4%77.6%66.4%69.0%70.0%62.4%70.0%70.2%
Operating margin36.4%33.8%19.5%39.0%24.8%31.9%31.2%23.5%16.2%24.6%
Net margin23.2%18.8%17.4%23.7%10.1%20.5%20.4%9.0%7.6%6.9%

Latest quarters

LineQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Revenue$14.5B$15.1B$13.3B$15.4B$15.8B$16.6B$15B$17B
Gross profit$10.2B*$10.7B$9.3B*$11.1B*$10.5B*$12.1B$10.8B*$12.7B*
Operating income$3.8B-$1.5B*$3.7B$4.9B$1.9B$4.5B*$4B$6.4B
Net income$1.6B-$22M$1.3B$938M$186M$1.8B$695M$3.6B
EPS (diluted)$0.88-$0.02$0.72$0.52$0.10$1.02$0.39$2.03
Operating cash flow$5.4B*$7B*$1.6B$5.2B*$7B*$5.2B*$3.8B$3.4B*
Free cash flow$5.2B*$6.8B*$1.4B*$4.9B*$6.6B*$4.9B*$3.6B*$3.1B*
Cash & equivalents$7.3B$5.5B$5.2B$6.5B$5.6B$5.2B$9.4B$6.6B
Total debt$58.5B$66.8B$64.5B$63B$63B$64.5B$64.5B$62.5B
Gross margin70.9%70.9%70.0%71.8%66.4%72.6%71.9%74.7%
Operating margin26.5%-9.9%28.0%31.7%12.1%27.3%26.6%37.9%
Net margin10.8%-0.1%9.6%6.1%1.2%10.9%4.6%21.3%

Revenue by region

LineFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
United States$18.3B$21.5B$23.9B$34.9B$43.5B$45.7B$41.9B$43B$46.6B
All other countries$4.1B$4B$4B$4B$4.8B$4.8B$5B$5.4B$5.8B
Germany$1.2B$1.3B$909M$1B$1.2B$1.3B$1.3B$1.5B$1.7B
Japan$764M$1.6B$1.2B$1.2B$1.1B$956M$1B$1.1B$1.3B
Canada$659M$730M$813M$1.2B$1.4B$1.2B$1.1B$1.1B$1.2B
China---$471M$857M$912M$950M$917M$1B
France$730M$783M$695M$797M$936M$787M$780M$776M$806M
United Kingdom$807M$855M$372M$509M$497M$462M$417M$522M$626M
Spain$521M$611M$472M$453M$519M$506M$501M$528M$609M
Italy$475M$652M$372M$379M$506M$444M$484M$511M$580M
Brazil$410M$350M$359M$406M$368M$430M$439M$464M$478M
Australia---$527M$533M$508M$472M$463M$459M
The Netherlands$362M$352M$163M------

* derived: a fourth quarter as the year less the three filed quarters, or a remainder as the total less the parts. All other figures are as filed.

About this page

Every figure on this page is read from AbbVie Inc.'s own SEC filings: the statement lines from the SEC's XBRL company-facts feed, the revenue splits from the segment and revenue notes of each 10-K and 10-Q. Nothing is typed in or estimated. The cache refreshes daily.

Read the Risk & Quality report on AbbVie Inc. or see all companies.

More in Healthcare & Pharma